Proteogenomics connects somatic mutations to signaling in breast cancer

[1]  T. Doman,et al.  Identification of Druggable Cancer Driver Genes Amplified across TCGA Datasets , 2014, PloS one.

[2]  Susan E. Abbatiello,et al.  Targeted Peptide Measurements in Biology and Medicine: Best Practices for Mass Spectrometry-based Assay Development Using a Fit-for-Purpose Approach* , 2014, Molecular & Cellular Proteomics.

[3]  K. Nakayama,et al.  Ubiquitin ligases: cell-cycle control and cancer , 2006, Nature Reviews Cancer.

[4]  Xiang-Jiao Yang,et al.  The Tumor Suppressor Kinase LKB1 Activates the Downstream Kinases SIK2 and SIK3 to Stimulate Nuclear Export of Class IIa Histone Deacetylases* , 2013, The Journal of Biological Chemistry.

[5]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[6]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  S. Nakajima,et al.  Differential phosphorylation of DNA-PKcs regulates the interplay between end-processing and end-ligation during nonhomologous end-joining. , 2015, Molecular cell.

[8]  Jeffrey R. Whiteaker,et al.  Proteogenomic characterization of human colon and rectal cancer , 2014, Nature.

[9]  G. Getz,et al.  Inferring tumour purity and stromal and immune cell admixture from expression data , 2013, Nature Communications.

[10]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[11]  Yiling Lu,et al.  AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. , 2009, Cancer cell.

[12]  T. Golub,et al.  A method for high-throughput gene expression signature analysis , 2006, Genome Biology.

[13]  J. Chernoff,et al.  Targeting the kinase effectors of RHO-family GTPases , 2014 .

[14]  Jernej Ule,et al.  The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes. , 2011, Genes & development.

[15]  Steven J. M. Jones,et al.  Circos: an information aesthetic for comparative genomics. , 2009, Genome research.

[16]  I. Ellis,et al.  Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents , 2015, Breast Cancer Research.

[17]  Li Ding,et al.  An Analysis of the Sensitivity of Proteogenomic Mapping of Somatic Mutations and Novel Splicing Events in Cancer* , 2015, Molecular & Cellular Proteomics.

[18]  P. May,et al.  Cell cycle control and cancer. , 2000, Pathologie-biologie.

[19]  Sonali Rawat,et al.  Molecular Pathways: Targeting the Kinase Effectors of RHO-Family GTPases , 2014, Clinical Cancer Research.

[20]  Li Ding,et al.  Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. , 2013, Cell reports.

[21]  Francesca Petralia,et al.  New Method for Joint Network Analysis Reveals Common and Different Coexpression Patterns among Genes and Proteins in Breast Cancer , 2016, Journal of proteome research.

[22]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[23]  Mehdi Mesri,et al.  Connecting genomic alterations to cancer biology with proteomics: the NCI Clinical Proteomic Tumor Analysis Consortium. , 2013, Cancer discovery.

[24]  Mark D. Johnson,et al.  Numb Regulates Glioma Stem Cell Fate and Growth by Altering Epidermal Growth Factor Receptor and Skp1‐Cullin‐F‐Box Ubiquitin Ligase Activity , 2012, Stem cells.

[25]  G. Ravenscroft,et al.  SPEG interacts with myotubularin, and its deficiency causes centronuclear myopathy with dilated cardiomyopathy. , 2014, American journal of human genetics.

[26]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[27]  Ajay N. Jain,et al.  Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. , 2006, Cancer cell.

[28]  W. Symmans,et al.  Breast cancer heterogeneity: evaluation of clonality in primary and metastatic lesions. , 1995, Human pathology.

[29]  N. Bertos,et al.  Breast cancer - one term, many entities? , 2011, The Journal of clinical investigation.

[30]  Andrew D. Rouillard,et al.  LINCS Canvas Browser: interactive web app to query, browse and interrogate LINCS L1000 gene expression signatures , 2014, Nucleic Acids Res..

[31]  M. Scheffner,et al.  The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53 , 1993, Cell.

[32]  Anastasia Ivanova,et al.  TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Akhilesh Pandey,et al.  Activation of diverse signaling pathways by oncogenic PIK3CA mutations , 2014, Nature Communications.

[35]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[36]  Paul Ellis,et al.  PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor–positive breast cancer , 2010, Proceedings of the National Academy of Sciences.

[37]  Michael L. Gatza,et al.  Cross-species DNA copy number analyses identifies multiple 1q21-q23 subtype-specific driver genes for breast cancer , 2015, Breast Cancer Research and Treatment.

[38]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Kornelia Polyak,et al.  Heterogeneity in breast cancer. , 2011, The Journal of clinical investigation.

[40]  Todd R. Golub,et al.  PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling , 2011, Oncogene.

[41]  Marco Y. Hein,et al.  A Human Interactome in Three Quantitative Dimensions Organized by Stoichiometries and Abundances , 2015, Cell.

[42]  D. Radisky,et al.  Effective Targeting of Estrogen Receptor–Negative Breast Cancers with the Protein Kinase D Inhibitor CRT0066101 , 2015, Molecular Cancer Therapeutics.

[43]  Ronald J Moore,et al.  Ischemia in Tumors Induces Early and Sustained Phosphorylation Changes in Stress Kinase Pathways but Does Not Affect Global Protein Levels* , 2014, Molecular & Cellular Proteomics.

[44]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.